Genetics of Type 1 Diabetes
Overview
Authors
Affiliations
Background: Type 1 diabetes, a multifactorial disease with a strong genetic component, is caused by the autoimmune destruction of pancreatic β cells. The major susceptibility locus maps to the HLA class II genes at 6p21, although more than 40 non-HLA susceptibility gene markers have been confirmed.
Content: Although HLA class II alleles account for up to 30%-50% of genetic type 1 diabetes risk, multiple non-MHC loci contribute to disease risk with smaller effects. These include the insulin, PTPN22, CTLA4, IL2RA, IFIH1, and other recently discovered loci. Genomewide association studies performed with high-density single-nucleotide-polymorphism genotyping platforms have provided evidence for a number of novel loci, although fine mapping and characterization of these new regions remain to be performed. Children born with the high-risk genotype HLADR3/4-DQ8 comprise almost 50% of children who develop antiislet autoimmunity by the age of 5 years. Genetic risk for type 1 diabetes can be further stratified by selection of children with susceptible genotypes at other diabetes genes, by selection of children with a multiple family history of diabetes, and/or by selection of relatives that are HLA identical to the proband.
Summary: Children with the HLA-risk genotypes DR3/4-DQ8 or DR4/DR4 who have a family history of type 1 diabetes have more than a 1 in 5 risk for developing islet autoantibodies during childhood, and children with the same HLA-risk genotype but no family history have approximately a 1 in 20 risk. Determining extreme genetic risk is a prerequisite for the implementation of primary prevention trials, which are now underway for relatives of individuals with type 1 diabetes.
Immune checkpoint inhibitor-related type 1 diabetes incidence, risk, and survival association.
Kamitani F, Nishioka Y, Koizumi M, Nakajima H, Kurematsu Y, Okada S J Diabetes Investig. 2024; 16(2):334-342.
PMID: 39569589 PMC: 11786175. DOI: 10.1111/jdi.14362.
Zhou L, Yang S, Li Y, Xue C, Wan R Front Immunol. 2024; 15:1448728.
PMID: 39559363 PMC: 11570264. DOI: 10.3389/fimmu.2024.1448728.
Circulating hsa-miR-320a and its regulatory network in type 1 diabetes mellitus.
Nizam R, Malik M, Jacob S, Alsmadi O, Koistinen H, Tuomilehto J Front Immunol. 2024; 15:1376416.
PMID: 39464889 PMC: 11502356. DOI: 10.3389/fimmu.2024.1376416.
Qian Y, Chen S, Wang Y, Zhang Y, Zhang J, Jiang L BMC Med. 2024; 22(1):357.
PMID: 39227839 PMC: 11373477. DOI: 10.1186/s12916-024-03583-w.
Antigen-specific T cell responses in autoimmune diabetes.
Dwyer A, Shaheen Z, Fife B Front Immunol. 2024; 15:1440045.
PMID: 39211046 PMC: 11358097. DOI: 10.3389/fimmu.2024.1440045.